The post-market phase is the phase following the placement of medical devices on the market. ISO 14971 also refers to the post-production phase after development and production.
Content
This page provides a quick overview of the articles on the post-market phase:
The post-market or post-production phase comprises all activities after production until the decommissioning/decommissioning of the devices, at the latest, at the end of their service life. These activities also include use and maintenance.
Fig. 1: The post-market phase is an important part of the product life cycle.
The international regulatory requirements for the post-market phase are increasing. The EU MDR and IVDR regulations are evidence of this. In addition, there are national regulations, such as 21 CFR part 822 on post-market surveillance, and national laws and regulations on vigilance, such as the German law MPAIMV.
There are also guidelines, such as MDCG 2022-21 and MDCG 2020-6, and laws that apply to all devices, such as the Product Liability Act, which also requires post-market activities such as monitoring.
The regulations oblige manufacturers to carry out post-market surveillance, for example. To this end, manufacturers must draw up a post-market surveillance plan and collect and evaluate the post-market surveillance data in accordance with this plan. Manufacturers find it particularly difficult to analyze trends. The output then flows into reports such as the Periodic Safety Update Report (PSUR).
Depending on the class of the devices, the reports must also be published in EUDAMED.
One part of post-market surveillance is the post-market clinical follow-up (PMCF). This involves collecting clinical data to keep the clinical evaluation up to date. If the data is insufficient, PMCF studies may be necessary.
If serious incidents or trends leading to an unacceptable risk are observed in the post-market phase, manufacturers must notify the authorities (vigilance) and take corrective action.
Post-market activities include monitoring new regulations (regulatory update), monitoring vulnerabilities in off-the-shelf software, and eliminating these vulnerabilities with security patches.
These activities are not only the responsibility of manufacturers, for example, their product managers, quality management representatives, medical device consultants, and responsible persons.
Suppliers, importers, and distributors also have obligations in this post-production phase.
The essential objective of all these activities is to ensure patient safety, i.e., to minimize risks from unsafe devices.
For this reason, the third edition of the risk management standard ISO 14971 has increased the requirements for the post-production phase. The associated Technical Report ISO/TR 24971 describes these requirements in more detail.
To assess the benefit-risk ratio, manufacturers must continuously monitor and consider the state of the art.
Not doing so is one of the most common mistakes in risk management.
Do you still have questions about the post-market phase? Then, take advantage of our free micro-consulting.
If you want to delve deeper into the topic, we offer video training courses at the Medical Device University.
The post-market services take a large part of the work off your hands, from monitoring the regulations to post-market surveillance. This enables you to achieve:
Contact us if you would like support.
Post-Market Surveillance (PMS) is a proactive and systematic process to derive necessary corrective and preventive actions (CAPA) from information about medical devices already placed on the market. We have created a Post-Market Surveillance checklist for you. With this checklist, you can find out whether you meet the regulatory requirements of the MDR for Post-Market Surveillance…
DetailsCurrently, manufacturers of legacy devices can keep their devices on the market without demonstrating conformity under Regulation 2017/745 on Medical Devices (MDR). However, manufacturers will have to provide the necessary clinical data by the end of the transition period at the latest. The requirements for clinical data that can be used to demonstrate conformity have increased enormously under the MDR. Furthermore,…
DetailsThe medical device regulations have significantly increased the requirements for distributors. You need to understand these requirements to avoid multi-year custodial sentences threatened in the event of infringement. This article also considers extensive guidance issued by the Irish regulator. 1. What a “distributor” is (and what it isn’t) a) Definition The Medical Device Regulation (MDR) has many…
DetailsManufacturers of substance-based medical devices such as seawater nasal sprays, mucous membrane-soothing cough syrups, or osmotically active laxatives face several challenges once the Regulation (EU) 2017/745 (MDR) came into force: This article illustrates what can be done to overcome the regulatory hurdles and ensure the marketability of your substance-based medical devices beyond the transition…
DetailsWith the Post-Market Surveillance plan (PMS plan), manufacturers are trying to achieve two (potentially) contradictory goals. On the one hand, they have to comply with the legal requirements and maximize the safety of their devices. And on the other, they can only take on as much work as they can realistically do in the long…
DetailsMedical device manufacturers are required to carry out a regular “regulatory update.” Because as strange as it sounds, regulatory requirements oblige manufacturers to continuously monitor and evaluate changes to regulatory requirements and take any necessary measures. Keeping track of thousands of regulatory requirements is a challenge. Manufacturers should have a clear understanding of the typical…
Details